“As a result of our successes demonstrated by administering SPRYNG in a large number of companion animals and horses, we are highly encouraged by the prospect of enhancing the lives of people suffering from a variety of medical afflictions, such as osteoarthritis,” said John Lai PetVivo’s Chief Executive Officer. “We are looking forward to moving one or more products through the regulatory process as quickly as possible so that we can begin commercialization in a number of very large market sectors.”

https://www.petvivo.com/about

https://twitter.com/petvivo

https://www.petvivocares.org/

****** The views expressed in Markets Hunter's content, productions, or other investor relations materials and presentations may be subject to change. Neither Markets Hunter nor any of its data or content providers shall be held responsible for any errors or delays in the content, or for any actions taken based on the information provided. All data and information is intended to be used for informational or entertainment purposes only. On occasion, we enter into contracts with third parties or publicly traded companies and receive financial remuneration in exchange for disseminating information and opinions regarding the company and the stock market such as this video. Markets Hunter is not a licensed broker-dealer or registered investment advisor. The content and productions of Markets Hunter are sourced from reliable data sources, though accuracy and completeness are not guaranteed. Consequently, the information should not be seen as tailored advice to any individual investor's specific needs. Markets Hunter.com is devoted to furnishing our readers with beneficial insights into publicly traded companies.